Effect of age on the association between p16CDKN2A methylation and DNMT3B polymorphism in head and neck carcinoma and patient survival

International Journal of Oncology

Volumn 37, Issue 1, 2010, Pages 167-176

  Farias, Lucyana Conceição ^a   Fraga, Carlos Alberto De Carvalho ^a   De Oliveira, Marcos Vinícius Macedo ^a   Silva, Thiago Fonseca ^a   Marques Silva, Luciano ^b   Moreira, Paula Rocha ^b   De Paula, Alfredo Maurício Batista ^a   Gomez, Ricardo Santiago ^b   Guimarães, André Luiz Sena ^a  

^a STATE UNIVERSITY OF MONTES CLAROS   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

DNMT3B; Head and neck cancer; Methylation; p16CDKN2; Polymorphism

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; DNA METHYLTRANSFERASE 3B; DNA (CYTOSINE 5) METHYLTRANSFERASE;

ADULT; AGE DISTRIBUTION; AGED; ALLELE; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CASE CONTROL STUDY; CONTROLLED STUDY; DNA METHYLATION; FAMILY HISTORY; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HEAD AND NECK CARCINOMA; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; SQUAMOUS CELL CARCINOMA; AGE; CARCINOMA, SQUAMOUS CELL; FAMILY HEALTH; GENETICS; HEAD AND NECK NEOPLASMS; MIDDLE AGED; MORTALITY; PHYSIOLOGY; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TUMOR SUPPRESSOR GENE; VERY ELDERLY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; FAMILY HEALTH; FEMALE; GENES, P16; GENOME-WIDE ASSOCIATION STUDY; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; SMOKING;

EID: 77953228419     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000664     Document Type: Article

References (69)

1. Parkin DM: Global cancer statistics in the year 2000. Lancet Oncol 2: 533-543, 2001.
2. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
3. Argiris A, Karamouzis MV, Raben D and Ferris RL: Head and neck cancer. Lancet 371: 1695-1709, 2008.
4. National Cancer Institute (INCA): Estimate 2008: Brazilian cancer incidence. http://www inca gov br/regpop. Instituto Nacional de Câncer.Coordenação de Prevenção e Vigilância, 2007.
5. Argiris A and Eng C: Epidemiology, staging and screening of head and neck cancer. Cancer Res Treat 114: 15-60, 2003.
6. De Paula AM, Souza LR, Farias LC, et al: Analysis of 724 cases of primary head and neck squamous cell carcinoma (HNSCC) with a focus on young patients and p53 immunolocalization. Oral Oncol 45: 777-782, 2009.
7. Garavello W, Spreafico R and Gaini RM: Oral tongue cancer in young patients: a matched analysis. Oral Oncol 43: 894-897, 2007.
8. Gawecki W, Kostrzewska-Poczekaj M, Gajecka M, Milecki P, Szyfter K and Szyfter W: The role of genetic factor in etiopathogenesis of squamous cell carcinoma of the head and neck in young adults. Eur Arch Otorhinolaryngol 264: 1459-1465, 2007.
9. Llewellyn CD, Johnson NW and Warnakulasuriya S: Factors associated with delay in presentation among younger patients with oral cancer. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 97: 707-713, 2004.
10. Manuel S, Raghavan SK, Pandey M and Sebastian P: Survival in patients under 45 years with squamous cell carcinoma of the oral tongue. Int J Oral Maxillofac Surg 32: 167-173, 2003.
11. Myers JN, Elkins T, Roberts D and Byers RM: Squamous cell carcinoma of the tongue in young adults: increasing incidence and factors that predict treatment outcomes. Otolaryngol Head Neck Surg 122: 44-51, 2000.
12. Siriwardena BS, Tilakaratne A, Amaratunga EA, et al: Analysis of histopathological and immunohistochemical differences of oral squamous cell carcinoma in young and old patients in Sri Lanka. J Oral Pathol Med 36: 357-362, 2007.
13. Chitapanarux I, Lorvidhaya V, Sittitrai P, et al: Oral cavity cancers at a young age: analysis of patient, tumor and treatment characteristics in Chiang Mai University Hospital. Oral Oncol 42: 83-88, 2006. (Pubitemid 41831527)
14. Kannan K, Latha PN and Shanmugam G: Expression of bcl-2 oncoprotein in Indian oral squamous cell carcinomas. Oral Oncol 34: 373-376, 1998. (Pubitemid 28440298)
15. Scully C, Field JK and Tanzawa H: Genetic aberrations in oral or head and neck squamous cell carcinoma (SCCHN): 1. Carcinogen metabolism, DNA repair and cell cycle control. Oral Oncol 36: 256-263, 2000.
16. Toruner GA, Ulger C, Alkan M, et al: Association between gene expression profile and tumor invasion in oral squamous cell carcinoma. Cancer Genet Cytogenet 154: 27-35, 2004.
17. Herman JG and Baylin SB: Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349: 2042-2054, 2003. (Pubitemid 37448928)
18. Jones PA and Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet 3: 415-428, 2002.
19. Feinberg AP: The epigenetics of cancer etiology. Semin Cancer Biol 14: 427-432, 2004.
20. Momparler RL: Cancer epigenetics. Oncogene 22: 6479-6483, 2003.
21. Ducasse M and Brown MA: Epigenetic aberrations and cancer. Mol Cancer 5: 60, 2006.
22. Teodoridis JM, Strathdee G and Brown R: Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker. Drug Resist Updat 7: 267-278, 2004. (Pubitemid 39469099)
23. Gronbaek K, Hother C and Jones PA: Epigenetic changes in cancer. APMIS 115: 1039-1059, 2007.
24. Hermann A, Gowher H and Jeltsch A: Biochemistry and biology of mammalian DNA methyltransferases. Cell Mol Life Sci 61: 2571-2587, 2004. (Pubitemid 39586518)
25. Esteller M: CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene 21: 5427-5440, 2002.
26. Shaw RJ, Hall GL, Woolgar JA, Lowe D, Rogers SN, Field JK, Liloglou T and Risk JM: Quantitative methylation analysis of resection margins and lymph nodes in oral squamous cell carcinoma. Br J Oral Maxillofac Surg 45: 617-622, 2007.
27. Calmon MF, Colombo J, Carvalho F, et al: Methylation profile of genes CDKN2A (p14 and p16), DAPK1, CDH1 and ADAM23 in head and neck cancer. Cancer Genet Cytogenet 173: 31-37, 2007.
28. Auerkari EI: Methylation of tumor suppressor genes p16(INK4a), p27(Kip1) and E-cadherin in carcinogenesis. Oral Oncol 42: 5-13, 2006.
29. Jones JS, Amos CI, Pande M, et al: DNMT3b polymorphism and hereditary nonpolyposis colorectal cancer age of onset. Cancer Epidemiol Biomarkers Prev 15: 886-891, 2006.
30. Mizuno S, Chijiwa T, Okamura T, et al: Expression of DNA methyltransferases DNMT1, 3A and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia. Blood 97: 1172-1179, 2001.
31. Montgomery KG, Liu MC, Eccles DM and Campbell IG: The DNMT3B C→T promoter polymorphism and risk of breast cancer in a British population: a case-control study. Breast Cancer Res 6: R390-R394, 2004.
32. Nagai M, Nakamura A, Makino R and Mitamura K: Expression of DNA (5-cytosin)-methyltransferases (DNMTs) in hepatocellular carcinomas. Hepatol Res 26: 186-191, 2003.
33. Patra SK, Patra A, Zhao H and Dahiya R: DNA methyltransferase and demethylase in human prostate cancer. Mol Carcinog 33: 163-171, 2002.
34. Robertson KD, Uzvolgyi E, Liang G, et al: The human DNA methyltransferases (DNMTs) 1, 3a and 3b: coordinate mRNA expression in normal tissues and overexpression in tumors. Nucleic Acids Res 27: 2291-2298, 1999.
35. Chang KP, Hao SP, Liu CT, et al: Promoter polymorphisms of DNMT3B and the risk of head and neck squamous cell carcinoma in Taiwan: a case-control study. Oral Oncol 43: 345-351, 2007.
36. Liu Z, Wang L, Wang LE, Sturgis EM and Wei Q: Polymorphisms of the DNMT3B gene and risk of squamous cell carcinoma of the head and neck: a case-control study. Cancer Lett 268: 158-165, 2008.
37. Wang L, Rodriguez M, Kim ES, et al: A novel C/T polymorphism in the core promoter of human de novo cytosine DNA methyltransferase 3B6 is associated with prognosis in head and neck cancer. Int J Oncol 25: 993-999, 2004.
38. Shen H, Wang L, Spitz MR, Hong WK, Mao L and Wei Q: A novel polymorphism in human cytosine DNA-methyltransferase-3B promoter is associated with an increased risk of lung cancer. Cancer Res 62: 4992-4995, 2002.
39. Singal R, Das PM, Manoharan M, Reis IM and Schlesselman JJ: Polymorphisms in the DNA methyltransferase 3b gene and prostate cancer risk. Oncol Rep 14: 569-573, 2005.
40. Wu Y and Lin JS: DNA methyltransferase 3B promoter polymorphism and its susceptibility to primary hepatocellular carcinoma in the Chinese Han nationality population: a case-control study. World J Gastroenterol 13: 6082-6086, 2007.
41. Hogg RP, Honorio S, Martinez A, et al: Frequent 3p allele loss and epigenetic inactivation of the RASSF1A tumour suppressor gene from region 3p21.3 in head and neck squamous cell carcinoma. Eur J Cancer 38: 1585-1592, 2002.
42. Nakahara Y, Shintani S, Mihara M, Ueyama Y and Matsumura T: High frequency of homozygous deletion and methylation of p16(INK4A) gene in oral squamous cell carcinomas. Cancer Lett 163: 221-228, 2001.
43. Reed AL, Califano J, Cairns P, et al: High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res 56: 3630-3633, 1996.
44. Schneider BG, Gulley ML, Eagan P, Bravo JC, Mera R and Geradts J: Loss of p16/CDKN2A tumor suppressor protein in gastric adenocarcinoma is associated with Epstein-Barr virus and anatomic location in the body of the stomach. Hum Pathol 31: 45-50, 2000.
45. Yakushiji T, Uzawa K, Shibahara T, Noma H and Tanzawa H: Over-expression of DNA methyltransferases and CDKN2A gene methylation status in squamous cell carcinoma of the oral cavity. Int J Oncol 22: 1201-1207, 2003.
46. Esteller M: The coming of age of DNA methylation in medicine in the genomics and postgenomics era. Clin Immunol 103: 213-216, 2002.
47. INK4a promoter hypermethylation in non-smoking female lung cancer with human papillomavirus infection. Cancer Lett 226: 77-84, 2005.
48. INK4a correlates with higher DNMT3B expression in human oesophageal squamous cell carcinomas. Hum Exp Toxicol 25: 515-522, 2006.
49. Wang J, Walsh G, Liu DD, Lee JJ and Mao L: Expression of Delta DNMT3B variants and its association with promoter methylation of p16 and RASSF1A in primary non-small cell lung cancer. Cancer Res 66: 8361-8366, 2006.
50. Parra FC, Amado RC, Lambertucci JR, Rocha J, Antunes CM and Pena SD: Color and genomic ancestry in Brazilians. Proc Natl Acad Sci USA 100: 177-182, 2003.
51. Pimenta JR, Zuccherato LW, Debes AA, et al: Color and genomic ancestry in Brazilians: a study with forensic microsatellites. Hum Hered 62: 190-195, 2006.
52. Sobin LH: TNM: evolution and relation to other prognostic factors. Semin Surg Oncol 21: 3-7, 2003.
53. Broders AC: Squamous-cell epithelioma of the skin: a study of 256 cases. Ann Surg 73: 141-160, 1921.
54. Bryne M, Nielsen K, Koppang HS and Dabelsteen E: Reproducibility of two malignancy grading systems with reportedly prognostic value for oral cancer patients. J Oral Pathol Med 20: 369-372, 1991.
55. Goldenberg D, Harden S, Masayesva BG, et al: Intraoperative molecular margin analysis in head and neck cancer. Arch Otolaryngol Head Neck Surg 130: 39-44, 2004.
56. Moreira PR, Guimaraes MM, Guimaraes AL, et al: Methylation of P16, P21, P27, RB1 and P53 genes in odontogenic keratocysts. J Oral Pathol Med 38: 99-103, 2009.
57. Xiao Y, Word B, Starlard-Davenport A, Haefele A, Lyn-Cook BD and Hammons G: Age and gender affect DNMT3a and DNMT3b expression in human liver. Cell Biol Toxicol 24: 265-272, 2008.
58. Hasegawa M, Nelson HH, Peters E, Ringstrom E, Posner M and Kelsey KT: Patterns of gene promoter methylation in squamous cell cancer of the head and neck. Oncogene 21: 4231-4236, 2002.
59. Kato K, Hara A, Kuno T, et al: Aberrant promoter hypermethylation of p16 and MGMT genes in oral squamous cell carcinomas and the surrounding normal mucosa. J Cancer Res Clin Oncol 132: 735-743, 2006.
60. Kim DS, Cha SI, Lee JH, et al: Aberrant DNA methylation profiles of non-small cell lung cancers in a Korean population. Lung Cancer 58: 1-6, 2007.
61. Hecht SS: DNA adduct formation from tobacco-specific Nnitrosamines. Mutat Res 424: 127-142, 1999.
62. Tamae K, Kawai K, Yamasaki S, et al: Effect of age, smoking and other lifestyle factors on urinary 7-methylguanine and 8-hydroxydeoxyguanosine. Cancer Sci 100: 715-721, 2009.
63. Stillwell WG, Glogowski J, Xu HX, et al: Urinary excretion of nitrate, N-nitrosoproline, 3-methyladenine and 7-methylguanine in a Colombian population at high risk for stomach cancer. Cancer Res 51: 190-194, 1991.
64. Ichiba M, Matsumoto A, Kondoh T, Horita M and Tomokuni K: Decreasing urinary PAH metabolites and 7-methylguanine after smoking cessation. Int Arch Occup Environ Health 79: 545-549, 2006.
65. Drummond SN, De ML, Noronha JC and Gomez RS: GSTM1 polymorphism and oral squamous cell carcinoma. Oral Oncol 40: 52-55, 2004.
66. Gomes CC, Drummond SN, Guimaraes AL, Andrade CI, Mesquita RA and Gomez RS: P21/WAF1 and cyclin D1 variants and oral squamous cell carcinoma. J Oral Pathol Med 37: 151-156, 2008.
67. INK4a promoter hypermethylation in human papillomavirus-infected female lung cancer in Taiwan. Int J Cancer 113: 440-445, 2005.
68. Kong CS, Narasimhan B, Cao H, et al: The relationship between human papillomavirus status and other molecular prognostic markers in head and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 74: 553-561, 2009.
69. Sedaghat AR, Zhang Z, Begum S, et al: Prognostic significance of human papillomavirus in oropharyngeal squamous cell carcinomas. Laryngoscope 119: 1542-1549, 2009.